Stock Traders Purchase Large Volume of Put Options on Maravai LifeSciences (NASDAQ:MRVI)

Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) was the recipient of unusually large options trading activity on Wednesday. Traders acquired 1,002 put options on the stock. This represents an increase of approximately 1,791% compared to the typical volume of 53 put options.

Insider Transactions at Maravai LifeSciences

In other news, insider Carl Hull acquired 175,000 shares of Maravai LifeSciences stock in a transaction that occurred on Monday, November 11th. The stock was bought at an average price of $5.64 per share, with a total value of $987,000.00. Following the completion of the purchase, the insider now owns 175,000 shares in the company, valued at approximately $987,000. The trade was a ∞ increase in their ownership of the stock. The purchase was disclosed in a legal filing with the SEC, which is available through this link. Corporate insiders own 0.63% of the company’s stock.

Institutional Investors Weigh In On Maravai LifeSciences

Hedge funds have recently made changes to their positions in the business. Point72 Asia Singapore Pte. Ltd. bought a new stake in shares of Maravai LifeSciences in the 2nd quarter worth approximately $32,000. Venturi Wealth Management LLC bought a new stake in shares of Maravai LifeSciences in the 3rd quarter worth approximately $47,000. Custom Index Systems LLC bought a new stake in shares of Maravai LifeSciences in the 3rd quarter worth approximately $97,000. Y Intercept Hong Kong Ltd bought a new stake in shares of Maravai LifeSciences in the 3rd quarter worth approximately $105,000. Finally, Headlands Technologies LLC lifted its holdings in shares of Maravai LifeSciences by 205.9% in the 2nd quarter. Headlands Technologies LLC now owns 14,935 shares of the company’s stock worth $107,000 after acquiring an additional 10,053 shares during the last quarter. 50.25% of the stock is currently owned by institutional investors.

Maravai LifeSciences Price Performance

MRVI stock opened at $6.13 on Friday. The company has a debt-to-equity ratio of 0.89, a current ratio of 10.74 and a quick ratio of 9.94. Maravai LifeSciences has a one year low of $4.28 and a one year high of $11.56. The stock has a market cap of $1.55 billion, a PE ratio of -3.74 and a beta of -0.07. The firm has a 50 day simple moving average of $5.70 and a two-hundred day simple moving average of $7.42.

Analysts Set New Price Targets

Several brokerages recently commented on MRVI. Robert W. Baird reduced their price objective on shares of Maravai LifeSciences from $10.00 to $9.00 and set an “outperform” rating for the company in a research note on Friday, November 8th. Royal Bank of Canada reduced their price objective on shares of Maravai LifeSciences from $17.00 to $13.00 and set an “outperform” rating for the company in a research note on Friday, November 8th. Guggenheim began coverage on shares of Maravai LifeSciences in a research note on Thursday, December 19th. They set a “neutral” rating for the company. Wolfe Research assumed coverage on shares of Maravai LifeSciences in a research note on Thursday, November 14th. They set a “peer perform” rating for the company. Finally, The Goldman Sachs Group cut shares of Maravai LifeSciences from a “neutral” rating to a “sell” rating and cut their price target for the stock from $7.00 to $4.25 in a research note on Thursday, December 5th. One research analyst has rated the stock with a sell rating, five have assigned a hold rating and five have assigned a buy rating to the company. According to MarketBeat.com, Maravai LifeSciences currently has an average rating of “Hold” and a consensus target price of $10.28.

About Maravai LifeSciences

Maravai LifeSciences Holdings, Inc, a life sciences company, provides products to enable the development of drug therapies, diagnostics, novel vaccines, and support research on human diseases worldwide. The company’s products address the key phases of biopharmaceutical development and include nucleic acids for diagnostic and therapeutic applications, antibody-based products to detect impurities during the production of biopharmaceutical products, and products to detect the expression of proteins in tissues of various species.